In Europe, according to one study, 40 percent of the population—about 320 million people—has “severely restricted” access to treatments for musculoskeletal diseases.

In Europe, according to one study, 40 percent of the population—about 320 million people—has “severely restricted” access to treatments for musculoskeletal diseases.

In Europe, according to one study, 40 percent of the population—about 320 million people—has “severely restricted” access to treatments for musculoskeletal diseases.